$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

$fhtx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000119312521085777 Filed on March 18, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$250.0K	$430.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.560M	$11.25M
YoY Change		67.41%
% of Gross Profit
Research & Development	$16.47M	$57.72M
YoY Change		30.1%
% of Gross Profit
Depreciation & Amortization	$570.0K	$1.300M	$400.0K
YoY Change	42.5%	87.59%
% of Gross Profit
Operating Expenses	$21.03M	$68.96M
YoY Change		35.0%
Operating Profit		-$68.53M
YoY Change		34.15%
Interest Expense	-$320.0K	$979.0K
YoY Change		81.3%
% of Operating Profit
Other Income/Expense, Net	$560.0K	-$269.0K
YoY Change		511.36%
Pretax Income	-$20.76M	-$68.80M
YoY Change		34.56%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$20.76M	-$68.80M
YoY Change		34.56%
Net Earnings / Revenue	-8304.0%	-16000.0%
Basic Earnings Per Share		-$6.23
Diluted Earnings Per Share	-$1.797M	-$6.23
COMMON SHARES
Basic Shares Outstanding	35.81M	11.05M shares
Diluted Shares Outstanding		11.05M shares

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$185.8M	$185.8M	$14.98M
YoY Change	1140.04%	1138.67%
Cash & Equivalents	$92.80M	$92.80M	$14.98M
Short-Term Investments	$92.98M	$93.00M	$0.00
Other Short-Term Assets	$4.900M	$4.900M
YoY Change		157.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$190.7M	$190.7M	$16.89M
YoY Change	1029.33%	1028.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.53M	$62.30M	$2.683M
YoY Change	627.84%	1583.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$842.0K	$2.600M	$11.00K
YoY Change	7554.55%	52.94%
Total Long-Term Assets	$64.91M	$64.90M	$5.457M
YoY Change	1089.43%	1101.85%
TOTAL ASSETS
Total Short-Term Assets	$190.7M	$190.7M	$16.89M
Total Long-Term Assets	$64.91M	$64.90M	$5.457M
Total Assets	$255.6M	$255.6M	$22.34M
YoY Change	1044.01%	1046.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.680M	$3.700M	$3.439M
YoY Change	7.01%	8.82%
Accrued Expenses	$9.161M	$13.00M	$3.701M
YoY Change	147.53%	182.61%
Deferred Revenue	$2.024M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$4.152M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$18.85M	$18.80M	$12.65M
YoY Change	48.96%	48.03%
LONG-TERM LIABILITIES
Long-Term Debt	$19.65M	$19.70M	$10.96M
YoY Change	79.32%	79.09%
Other Long-Term Liabilities	$0.00	$70.90M
YoY Change		35350.0%
Total Long-Term Liabilities	$19.65M	$90.60M	$10.96M
YoY Change	79.32%	708.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.85M	$18.80M	$12.65M
Total Long-Term Liabilities	$19.65M	$90.60M	$10.96M
Total Liabilities	$109.4M	$109.4M	$23.81M
YoY Change	359.42%	359.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$162.9M		-$94.14M
YoY Change	73.09%
Common Stock	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$146.2M	$146.2M	-$88.02M
YoY Change
Total Liabilities & Shareholders Equity	$255.6M	$255.6M	$22.34M
YoY Change	1044.01%	1046.19%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$20.76M	-$68.80M
YoY Change		34.56%
Depreciation, Depletion And Amortization	$570.0K	$1.300M	$400.0K
YoY Change	42.5%	87.59%
Cash From Operating Activities	-$10.66M	-$31.29M	-$25.48M
YoY Change	-58.16%	-32.48%
INVESTING ACTIVITIES
Capital Expenditures	-$7.490M	$16.18M	-$180.0K
YoY Change	4061.11%	1571.8%
Acquisitions
YoY Change
Other Investing Activities	-$92.73M	-$92.73M	$0.00
YoY Change
Cash From Investing Activities	-$100.2M	-$108.9M	-$170.0K
YoY Change	58852.94%	11198.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	128.5M	$217.5M	8.640M
YoY Change	1387.38%	807.31%
NET CHANGE
Cash From Operating Activities	-10.66M	-$31.29M	-25.48M
Cash From Investing Activities	-100.2M	-$108.9M	-170.0K
Cash From Financing Activities	128.5M	$217.5M	8.640M
Net Change In Cash	17.63M	$77.27M	-17.01M
YoY Change	-203.64%	-431.22%
FREE CASH FLOW
Cash From Operating Activities	-$10.66M	-$31.29M	-$25.48M
Capital Expenditures	-$7.490M	$16.18M	-$180.0K
Free Cash Flow	-$3.170M	-$47.47M	-$25.30M
YoY Change	-87.47%	0.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15000000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14600000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7032000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1671000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	61000
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	418000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1346000
CY2019Q4	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	530000
CY2020Q4	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	1000000
CY2019Q4	fhtx	Long Term Debt Noncurrent Before Debt Discount And Accrued Payments LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments	10848000
CY2020Q4	fhtx	Long Term Debt Noncurrent Before Debt Discount And Accrued Payments LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments	20000000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4152000
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	57000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000
CY2019Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1384000
CY2020Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2146000
CY2019Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	119000
CY2020Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	2385000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1867000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3513000
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	367000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	250000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2400000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	420000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	660000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40585000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17255000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23330000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	77273000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23969000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	217473000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	691000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1221000
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	15294000
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	89861000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-964000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108914000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	968000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16183000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46335000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31286000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	14570000
CY2019	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1160000
CY2020	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	15135000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2137000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3194000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1211000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	474000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	991000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4670000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	99000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	238000
CY2019	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	1100000
CY2020	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	4201000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	693000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1327000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1694000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2961000
CY2019	us-gaap	Profit Loss ProfitLoss	-51128000
CY2020	us-gaap	Profit Loss ProfitLoss	-68800000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-39273000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2961000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1221000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1694000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	691000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4191793
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11046802
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.20
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.23
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-44000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-269000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000
CY2019	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	495000
CY2020	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	1001000
CY2019	us-gaap	Interest Expense InterestExpense	540000
CY2020	us-gaap	Interest Expense InterestExpense	979000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-51084000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-68531000
CY2019	us-gaap	Operating Expenses OperatingExpenses	51084000
CY2020	us-gaap	Operating Expenses OperatingExpenses	68961000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6722000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11246000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44362000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57715000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	430000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-88016000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94136000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162936000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6120000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22342000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255594000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	309126000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	86544000
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Liabilities Liabilities	23814000
CY2020Q4	us-gaap	Liabilities Liabilities	109407000
CY2019Q4	fhtx	Preferred Stock Warrants Liability PreferredStockWarrantsLiability	45000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12546000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	157000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58361000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10960000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19654000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12652000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18846000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2024000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4152000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1360000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3981000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3701000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9161000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3439000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3680000
CY2019Q4	us-gaap	Assets Assets	22342000
CY2020Q4	us-gaap	Assets Assets	255594000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1030000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42804000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2683000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19528000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	16885000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	190687000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1363000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4917000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	541000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14981000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92795000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	60000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1217000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	547000
CY2020	us-gaap	Lease Cost LeaseCost	8310000
CY2019	us-gaap	Lease Cost LeaseCost	2278000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3086000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1731000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	38306000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	271000
CY2020	fhtx	Change In Operating Lease Liability Right Of Use Asset Remeasurement ChangeInOperatingLeaseLiabilityRightOfUseAssetRemeasurement	7384000
CY2019	fhtx	Change In Operating Lease Liability Right Of Use Asset Remeasurement ChangeInOperatingLeaseLiabilityRightOfUseAssetRemeasurement	6513000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0753
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15104000
CY2020Q4	fhtx	Lessee Operating Lease Liability Estimated Lease Incentives LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives	3933000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4870851
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790946
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	833000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13500000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7M6D
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001822462
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	206000
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15530000
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21631000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3975000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2103000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1292000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3886489
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	176405000
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	188000
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-222000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1000
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	92981000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	122121000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	19800000
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	7984000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	9167000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10000000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	184742000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	700000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26621000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48383000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	763000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14513000
CY2019Q4	fhtx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	281000
CY2019Q4	fhtx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	482000
CY2020Q4	fhtx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	2819000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27384000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62896000
CY2019Q4	fhtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	414000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	522000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1010000
CY2019Q4	fhtx	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	190000
CY2020Q4	fhtx	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	174000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2415000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4955000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23769000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39289000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.299
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.316
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.022
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.037
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.071
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.064
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15300000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21800000
CY2020	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	92975000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20253854
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5034905
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51128000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68807000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-222000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of credit risk and of significant suppliers </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December 31, 2020, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials. </div></div></div> <div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of stock-based awards and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	15467863
CY2019Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	86782000
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	86544000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	28615546
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	28629622
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	27683000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.91
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1508122
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	76941000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y6M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.93
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5016460
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	76941000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.93
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5016460
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.10
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	181358
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.99
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	611048
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.87
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1922377
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.39
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.782
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.785
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5762745
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36790946
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	46600000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4800000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	3300000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	114000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	81379000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	30500000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10595000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10347000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10107000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10016000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9814000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92975000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92982000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2274000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1733000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-51128000
CY2020Q4	dei	Entity Public Float EntityPublicFloat	291700000
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.54
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.01
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62342000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	979000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	274000
CY2020Q4	fhtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	17032000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	436000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	74000
CY2020Q4	fhtx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	11694000
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28615546
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Entity Registrant Name EntityRegistrantName	Foghorn Therapeutics Inc.
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2020	dei	Trading Symbol TradingSymbol	FHTX
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36816714
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0

Files In Submission

Name	View Source	Status
0001193125-21-085777-index-headers.html	Edgar Link	pending
0001193125-21-085777-index.html	Edgar Link	pending
0001193125-21-085777.txt	Edgar Link	pending
0001193125-21-085777-xbrl.zip	Edgar Link	pending
d105868d10k.htm	Edgar Link	pending
d105868dex1018.htm	Edgar Link	pending
d105868dex231.htm	Edgar Link	pending
d105868dex311.htm	Edgar Link	pending
d105868dex312.htm	Edgar Link	pending
d105868dex321.htm	Edgar Link	pending
d105868dex322.htm	Edgar Link	pending
d105868dex46.htm	Edgar Link	pending
fhtx-20201231.xml	Edgar Link	completed
fhtx-20201231.xsd	Edgar Link	pending
fhtx-20201231_cal.xml	Edgar Link	unprocessable
fhtx-20201231_def.xml	Edgar Link	unprocessable
fhtx-20201231_lab.xml	Edgar Link	unprocessable
fhtx-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g105868g00g23.jpg	Edgar Link	pending
g105868g02s39.jpg	Edgar Link	pending
g105868g03r21.jpg	Edgar Link	pending
g105868g05d92.jpg	Edgar Link	pending
g105868g05j33.jpg	Edgar Link	pending
g105868g08g84.jpg	Edgar Link	pending
g105868g14e02.jpg	Edgar Link	pending
g105868g17c48.jpg	Edgar Link	pending
g105868g23f27.jpg	Edgar Link	pending
g105868g28m19.jpg	Edgar Link	pending
g105868g33c86.jpg	Edgar Link	pending
g105868g41v33.jpg	Edgar Link	pending
g105868g46u77.jpg	Edgar Link	pending
g105868g48e61.jpg	Edgar Link	pending
g105868g52h11.jpg	Edgar Link	pending
g105868g53c77.jpg	Edgar Link	pending
g105868g54l66.jpg	Edgar Link	pending
g105868g59b86.jpg	Edgar Link	pending
g105868g60p32.jpg	Edgar Link	pending
g105868g62s71.jpg	Edgar Link	pending
g105868g66l79.jpg	Edgar Link	pending
g105868g72z06.jpg	Edgar Link	pending
g105868g73f73.jpg	Edgar Link	pending
g105868g74u24.jpg	Edgar Link	pending
g105868g75b52.jpg	Edgar Link	pending
g105868g77c24.jpg	Edgar Link	pending
g105868g77m50.jpg	Edgar Link	pending
g105868g78v37.jpg	Edgar Link	pending
g105868g79y27.jpg	Edgar Link	pending
g105868g80r02.jpg	Edgar Link	pending
g105868g83b78.jpg	Edgar Link	pending
g105868g85n13.jpg	Edgar Link	pending
g105868g86q07.jpg	Edgar Link	pending
g105868g87w79.jpg	Edgar Link	pending
g105868g88t46.jpg	Edgar Link	pending
g105868g95v85.jpg	Edgar Link	pending
g105868g97b09.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

2020 Q4 Form 10-K Financial Statement

#000119312521085777 Filed on March 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX Foghorn Therapeutics Inc. Stock $fhtx

2020 Q4 Form 10-K Financial Statement

#000119312521085777 Filed on March 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx